Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All drugs

Axitinib (off Label)

Inlyta

Stage Phase 2

Sponsor Pfizer (investigator studies)

Route oral

Modality small molecule

Class VEGFR TKI

Mechanism VEGFR1 to 3 inhibitor (label class)

Target VEGFR1 to 3 (KDR, FLT1, FLT4) (TEC-0075)

Sources

fda, as of 2026-11-07

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a903e31-936e-4ed7-8a59-59f32374f338

Inlyta (axitinib) USPI, DailyMed setid 8a903e31-936e-4ed7-8a59-59f32374f338, published 03.16.2026, re-opened 2026-10-27 (raw/dailymed/inlyta.txt). The label has no adenoid cystic carcinoma indication (text search, 0 hits). Starting dose 5 mg twice daily; first dose reduction to 3 mg twice daily.

Brief source A2

guideline, as of 2026-11-07

https://www.esmoopen.com/article/S2059-7029(22)00232-0/fulltext

van Herpen C et al. Salivary gland cancer: ESMO-EURACAN Clinical Practice Guideline, ESMO Open, published 11.02.2022, doi 10.1016/j.esmoop.2022.100602 (guideline; opened in full 2026-10-27, four years old). AdCC section: no systemic treatment shown to improve OS in R/M AdCC; 10-year OS 40%; active surveillance for selected patients; systemic treatment for progressive or symptomatic disease; cisplatin 13% and CAP 25% response; antiangiogenics did not exceed 15% response; immune checkpoint inhibitors alone null; NOTCH inhibitor trial recommended for activated NOTCH; watch-and-wait for lung-only metastases; consider angiogenesis inhibitors or platinum chemotherapy when starting systemic treatment. The text says axitinib beat placebo; the trial's control was observation (see A21). NCCN could not be opened.

Brief source A7

publication, as of 2026-11-07

https://pubmed.ncbi.nlm.nih.gov/34315722/

Kang EJ et al. Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma, Clin Cancer Res 2021, doi 10.1158/1078-0432.CCR-21-1061, PMID 34315722 (publication abstract; opened 2026-10-27): n 60, progression within 9 months required, crossover allowed; axitinib 5 mg twice daily; 6-month PFS 73.0% vs 23.0%; median PFS 10.8 vs 2.8 months; ORR 0.0%; DCR 100% vs 51.9%; median OS not reached vs 27.2 months (P 0.226). PFS hazard ratio 0.25 (95% CI 0.14 to 0.48) is from the ESMO guideline (A7).

Brief source A21

publication, as of 2026-11-07

https://pubmed.ncbi.nlm.nih.gov/36898078/

Ferrarotto R et al. Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma, J Clin Oncol 2023, PMID 36898078 (publication abstract; opened 2026-10-27): 40 enrolled, 28 evaluable; confirmed ORR 18% (95% CI 6.1 to 36.9); median PFS 7.3 months (3.7 to 11.2); 6-month PFS 57%; median OS 16.6 months; serious TRAEs 29% (all grade 3); avelumab discontinued by 12%; axitinib dose reduced in 26%. An earlier search-record figure of 7.4 months PFS is superseded by this abstract.

Brief source A22

publication, as of 2026-11-07

https://pubmed.ncbi.nlm.nih.gov/41973043/

Axitinib plus Avelumab in R/M ACC: Biomarker Analysis and Updated Results of the Phase II Trial, Clin Cancer Res 2026, doi 10.1158/1078-0432.ccr-25-4599, PMID 41973043 (publication abstract; opened 2026-10-27): 28 patients; median PFS 1.8 months for ACC-I vs 11.4 months for ACC-II (HR 0.14, P below 0.0001); the abstract says the regimen entered NCCN guidelines as the first immunotherapy-based option for ACC (NCCN itself not opened); 167-gene immune signature predicted benefit with immunotherapy combinations.

Brief source A23

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT02859012

Randomized Phase II Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

Axitinib vs observation (randomized Phase 2)

Registry NCT02859012

Phase Phase 2

Status Completed

Enrollment 60

Start 2016-09

Primary completion 2017-12

Study completion 2020-08

Axitinib 5 mg twice daily

Dose 5 mg

Regimen twice daily

Comparator observation

Population R/M ACC with progression within 9 months (n = 60 total)

Estimand ITT

median progression-free survival: 10.8 months, primary analysis

6-month progression-free survival: 73%, 6 months

progression-free survival hazard ratio vs observation: 0.25 HR, as reported in ESMO-EURACAN guideline

objective response rate: 0%, primary analysis

disease control rate: 100%, primary analysis

Observation

Dose none

Population R/M ACC with progression within 9 months

Estimand ITT

median progression-free survival: 2.8 months, primary analysis

6-month progression-free survival: 23%, 6 months

disease control rate: 51.9%, primary analysis

median overall survival: 27.2 months, axitinib median not reached; P 0.226

Axitinib + avelumab Phase 2 (MD Anderson)

Phase Phase 2

Status Completed

Enrollment 40

Axitinib + avelumab

Dose axitinib 5 mg twice daily + avelumab

Population R/M ACC (n = 28 evaluable)

Estimand Single arm

confirmed objective response rate: 18%, primary analysis

median progression-free survival: 7.3 months, primary analysis

median overall survival: 16.6 months, primary analysis

serious treatment-related adverse events: 29%, primary analysis

Axitinib + avelumab, ACC-I subtype

Dose as above

Population ACC-I (exploratory biomarker analysis of 28 patients)

Estimand Single arm

median progression-free survival: 1.8 months, updated analysis; exploratory

Axitinib + avelumab, ACC-II subtype

Dose as above

Population ACC-II (exploratory)

Estimand Single arm

median progression-free survival: 11.4 months, updated analysis; HR 0.14 vs ACC-I